The state-of-the-art facility that complies with US FDA norms is coming up in the S P Biotech Park, Hyderabad with the location offering several advantages like single window clearance of all regulatory issues, tax holidays, common effluent treatment, uninterrupted power supply, wonderful landscape, housing colony, school and other related facilities.
Project will generate high revenues with proposed overall production of 342 kg of APIs. Higher production is possible within the same facility through company’s in-house R & D program and thus, possibility of higher revenues is evident.
100% EOU status.
Unique high value biopharmaceutical products and fewer competitions.
Higher returns are envisaged on capital employed
Minimum gestation period.
Company will be debt free after VII yrs and considers dividend to shareholders from the 2nd yr of operation.
SBIL comes under FDIP (Foreign Direct Investment Project) category and has brighter prospect for investments from NRI’s.
Proven and validated commercial Technology from the European collaborator and 100% Marketing arrangement with M/s Arch Pharmalabs Ltd., Mumbai.
The Company is backed by renowned Scientists and Technocrats in the field of biotechnology.